

# PRESS RELEASE

2024.04.22



## **Cell4Cure appoints Professor Jolanda de Vries, Radboud University Medical Center, Nijmegen, The Netherlands as Advisor for the continued development of Cell4Cure's Dendritic Cell Therapy**

**Solna, Sweden, 22 April 2024, Cell4Cure AB – a Swedish, private, cell therapy company world leading in the field of dendritic cell-mediated tolerance – today announced that they have appointed Dr Jolanda de Vries, professor and head of the department Medical BioSciences at Radboud university medical center, Nijmegen, The Netherlands as advisor to support the continued development of the company's dendritic cell therapy promoting antigen-specific tolerance.**

Cell4Cure AB appoints Dr Jolanda de Vries, Professor and head of the department Medical BioSciences at Radboud university medical center, Nijmegen, The Netherlands as advisor to support further development of the company's dendritic cell therapy promoting antigen-specific tolerance.

Professor Jan Holgersson, CSO: "Professor de Vries and her highly skilled team has already been involved in the successful establishment of a GMP-compliant manufacturing process of Cell4Cure's dendritic cell therapy to be used in Cell4Cure's first in human clinical trial, Toler8. We are all very happy to have Professor de Vries' continued support and look forward to further developments of the technology"

Professor de Vries: "I'm delighted to be involved in this exiting endeavour. The product has shown very promising properties in preclinical studies, and we can in a reproducible way manufacture this unique tolerogenic cell therapy on a larger scale enabling the start of the clinical trial program. I look forward to contributing to Cell4Cure's continued work to create a medical solution to the problem of neutralizing antibodies to coagulation factor VIII ", comments Professor Jolanda de Vries, Radboud university medical center".

# PRESS RELEASE

2024.04.22



For more information, please contact;  
Christina Herder, co-founder and board member  
Telephone: +46 703747156  
E-mail: [christina.herder@cell4cure.com](mailto:christina.herder@cell4cure.com)

## About Cell4Cure

Cell4Cure AB is a Swedish, privately held cell therapy company committed to the development of treatments for inducing of immune tolerance. The company's proprietary technology platform is based on dendritic cells mediating antigen-specific tolerance for the prevention or cure of diseases where the immune system is the enemy.

The company's first clinical study, *Toler8*, is focusing on inducing tolerance to FVIII thereby preventing the occurrence of FVIII inhibitors, i.e. neutralizing antibodies, in hemophilia A patients.

Cell4Cure will as a first step deliver value to patients and shareholders by advancing this program to clinical proof of concept.

For more information visit [\*\*www.cell4cure.com\*\*](http://www.cell4cure.com).